To further validate KLK2 as a novel target for prostate cancer, we developed two T cell–based therapeutic agents: KLK2 × CD3, a bispecific antibody redirecting CD3+ T cells to KLK2-expressing prostate cancer cells, and KLK2-targeted CAR T cells. Here, KLK2 is linked to prostate carcinoma.